Home / Posters / Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model

Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model
31 March 2017
By Keith Bowers

OracleBio presented a poster at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), on Sunday 2nd April in Washington D.C. The poster, made in collaboration with E-Therapeutics, is entitled ‘Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model’. The poster shows data from a study in which immunohistochemistry (IHC) was used in combination with digital image analysis to quantify CD4+ and CD8+ Tumor Infiltrating Lymphocytes (TILs) in  subcutaneous colorectal cancer tumours (CT-26)  treated with ETS2101 in combination with an anti-mCTLA4 checkpoint inhibitor. The study demonstrates how IHC combined with image analysis can be utilized to evaluate therapeutic response on TILs within the context of their tumor microenvironment.

The poster is available to view and download by clicking on the image below:

Explore OracleBio's Scientific Posters

OracleBio's Advanced Image Analysis Services

Stay up to date with OracleBio

Sign up to our mailing list to stay informed about news, webinars, events and more